The University of Chicago Header Logo

Steven Wolf

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
ORCID ORCID Icon0009-0008-2723-695X Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    The Wolf lab focuses on the characterization of the effective and failing T cell receptor (TCR)-repertoire to identify therapeutic TCR candidates for potential clinical translation. The gained insights can be applied to various immunotherapies since our research investigates the TCR-response of the host, which is the foundation to understand and utilize an effective immune response against any target.
    We study pre-clinical mouse models as well as human patient samples to translate findings from bench to bedside and back again. Current human cancers of interest are high-grade serous ovarian carcinoma, colorectal cancer, and acute myeloid leukemia. The main aim is advancing individualized TCR-T cell therapy against any type of cancer. To achieve this, the long-term goal is building a platform that allows the selection and validation of putative therapeutic TCR candidates. However, insights will also improve our understanding of various other immunotherapeutic interventions using vaccinations, tumor infiltrating lymphocytes (TILs) or immune checkpoint blockade (ICB).
    Our mouse models focus mainly on CD4+ T cells either alone or in combination with CD8+ T cells. We have a strong interest in the interaction of T cells with the cellularly and molecularly complex tumor microenvironment.

    Collapse Biography 
    Collapse education and training
    The University of Chicago, Chicago, USAPostdoc2023Immunotherapy
    Freie University Berlin, Berlin, GermanyPh.D.2020Cancer Immunology
    Johannes Gutenberg University, Mainz, GermanyDiploma2014Biomedical Chemistry

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Borges P, Vaz de Freitas M, Yoo J, Beruldsen F, Lewis J, Freitas de Sousa FJ, Choi SH, Nguyen DB, Zanatta G, Jang JH, Donadi E, Alachkar H, Wolf SP, Rigo MM, Jeon H, Antunes DA. Mapping the TCR landscape: computational tools empowering translational immunology and therapy design. J Immunother Cancer. 2026 Jun 18; 14(6). PMID: 42315254; PMCID: PMC13289238.
      Citations:    Fields:    Translation:HumansAnimals
    2. Anastasopoulou V, Schreiber H, Lee CE, Kiyotani K, Hansmann L, Nakamura Y, Leisegang M, Wolf SP. Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology. 2025 Dec; 14(1):2514041. PMID: 40515594; PMCID: PMC12169035.
      Citations:    Fields:    Translation:HumansAnimalsCells
    3. Rosenberger L, Hansmann L, Anastasopoulou V, Wolf SP, Drousch K, Moewes C, Feng X, Cao G, Huang J, Yew PY, Strønen E, Kato T, Saligrama N, Olweus J, Nakamura Y, Willimsky G, Blankenstein T, Schreiber H, Leisegang M. Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5). PMID: 40316304; PMCID: PMC12049912.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    4. Wolf SP, Leisegang M, Steiner M, Wallace V, Kiyotani K, Hu Y, Rosenberger L, Huang J, Schreiber K, Nakamura Y, Schietinger A, Schreiber H. CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy. Sci Immunol. 2024 09 13; 9(99):eadp6529. PMID: 39270007; PMCID: PMC11560124.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    5. Nakamura Y, Wolf SP, Anastasopoulou V, Drousch K, Diehl MI, Engels B, Yew PY, Kiyotani K, Schreiber K, Schreiber H, Leisegang M. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654. PMID: 38190111; PMCID: PMC11018470.
      Citations: 13     Fields:    Translation:HumansCells
    6. Ranoa DRE, Sharma P, Schane CP, Lewis AN, Valdez E, Marada VVVR, Hager MV, Montgomery W, Wolf SP, Schreiber K, Schreiber H, Bailey K, Fan TM, Hergenrother PJ, Roy EJ, Kranz DM. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer. 2023 05; 11(5). PMID: 37258040; PMCID: PMC10255004.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    7. Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31. PMID: 34619458; PMCID: PMC8901458.
      Citations: 1     Fields:    Translation:HumansAnimals
    8. Schreiber K, Hyjek E, Krausz T, Spiotto MT, Steiner M, Idel C, Booras H, Beck-Engeser G, Riederer J, Wolf SP, Karrison T, Jensen E, Weichselbaum RR, Nakamura Y, Yew PY, Lambert PF, Kurita T, Kiyotani K, Schreiber H, Böttinger P, Willimsky G, Leisegang M. Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 11 13; 41(11):1605-1615. PMID: 32221533; PMCID: PMC7896110.
      Citations: 5     Fields:    Translation:AnimalsCells
    9. Sharma P, Marada VVVR, Cai Q, Kizerwetter M, He Y, Wolf SP, Schreiber K, Clausen H, Schreiber H, Kranz DM. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):15148-15159. PMID: 32541028; PMCID: PMC7334454.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    10. Diehl MI, Bindokas VP, Schreiber H, Wolf SP. Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets. Exp Cell Res. 2020 08 15; 393(2):112014. PMID: 32439494; PMCID: PMC7415733.
      Citations: 5     Fields:    Translation:AnimalsCells
    11. Schreiber K, Karrison TG, Wolf SP, Kiyotani K, Steiner M, Littmann ER, Pamer EG, Schreiber H, Kammertoens T, Leisegang M. Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202. PMID: 31831634; PMCID: PMC7007920.
      Citations: 17     Fields:    Translation:AnimalsCells
    12. He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 Dec 05; 4(23). PMID: 31801912; PMCID: PMC6962012.
      Citations: 13     Fields:    
    Wolf's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (55)
    Explore
    _
    Co-Authors (7)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _